← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Trius Therapeutics, Inc.
San Diego, CA
$33,615,209
Total funding
6
Grants
Funding over time
peak $11.5M · FY2005–13$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$33,615,209 · 6
By mechanism
N01$29,327,344 · 2
R44$2,781,448 · 1
R43$1,504,417 · 2
R03$2,000 · 1
Investigators at Trius Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of Novel Agents for Gram-Negative Biodefense Pathogens$11,521,277
N01 · FY2008 · AI
Development of Novel Agents for Gram-Negative Biodefense Pathogens$8,680,866
N01 · FY2010 · AI
Development of Novel Agents for Gram-Negative Biodefense Pathogens$5,500,227
N01 · FY2012 · AI
A Novel Drug for Biodefense and Emerging Infectious Diseases$3,624,974
N01 · FY2013 · AI
Target and antibiotic discovery in Bacillus anthracis$1,075,096
R44 · FY2005 · AI
Target and antibiotic discovery in Bacillus anthracis$952,905
R44 · FY2004 · AI
Target and antibiotic discovery in Bacillus anthracis$753,447
R44 · FY2006 · AI
Novel Bacterial Cell Wall Biosynthesis Inhibitors for Biodefense Therapeutics$619,482
R43 · FY2007 · AI
Novel Bacterial Cell Wall Biosynthesis Inhibitors for Biodefense Therapeutics$585,743
R43 · FY2006 · AI
Novel Antibacterial Designed Multiple-Target Ligands$299,192
R43 · FY2006 · AI
Identification of Target-Specific Antimicrobials$2,000
R03 · FY2007 · MH